Mark Bussell

Mark Bussell

Auto-generated profile, based on publicly available information

Mark Bussell

Loma Linda University Health, Loma Linda, CA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2016 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
PDF file
AAAdel Alshahrani
Adel Alshahrani
MBMark Bussell
Mark Bussell
EJEric Johnson
Eric Johnson
BTBryan Tsao
Bryan Tsao
KBKhalid Bahjri
Khalid Bahjri

16 March 2026 in Integrative Cancer Therapies
Verified
Journal Article
Open access
JHJamie Hankins
Jamie Hankins
MBMark Bussell
Mark Bussell
LGLida Gharibvand
Lida Gharibvand
WJWon Jin Jeon
Won Jin Jeon
DCDani Ran Castillo
Dani Ran Castillo
GNGayathri Nagaraj
Gayathri Nagaraj
This study compared Intraneural Facilitation (INF ® ) therapy and standard physical therapy (PT) in preventing chemotherapy-induced peripheral neuropathy (CIPN) in women with newly diagnosed breast and gynecologic cancer. Thirty-eight women undergoing platinum and/or taxane-based chemotherapy, without prior peripheral neuropathy, were randomized into INF ® therapy (n = 20) and PT (n = 18). Treatments lasted 45 minutes, twice weekly, for 6 weeks. Neuropathy severity was evaluated using the Pain Quality Assessment Scale. Assessments were at baseline, 3 weeks, 6 weeks, and 3 months post-intervention. Acceptability, burden, and satisfaction were evaluated after 6 weeks. Among 38 patients, 12 (32%) experienced CIPN, with mean pain scores remaining mild (≤3) and no pharmacotherapy required until week 6. No adverse events were reported from the interventions. The INF ® therapy arm showed significant changes in numbness ( F = 6.030, P = .001, partial η 2 = 0.262) after week 6, while the PT arm showed significant changes in numbness ( Z = −2.39, P = .017), tingling ( Z = −2.84, P = .004), cramping ( Z = −2.120, P = .034), surface pain ( Z = −2.75, P = .006), and deep pain ( Z = −1.99, P = .046) between weeks 3 and 6. Nearly 80% of patients completed chemotherapy cycles with an average relative dose intensity of 90.4% (INF ® therapy: 87.73% vs PT: 73.44%). Ninety-four percent of patients were satisfied with their care, accepted the treatments, and perceived them as a low burden. The results demonstrated that INF ® therapy and PT are feasible options for CIPN, improving treatment adherence, outcomes, and quality of life for women with newly diagnosed breast and gynecological cancers. Trial Registration - The study was pre-registered on ClinicalTrials.gov (NCT03272919). August 8, 2017.